A phase Ib/IIa study assessing inhaled murepavadin for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Murepavadin (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions
- 22 Dec 2020 According to a Polyphor media release, this trial is expected to begin after the completion of the phase I study in 2021.
- 05 Dec 2020 New trial record
- 24 Nov 2020 According to a Polyphor media release, the company will be awarded, AGAward, from Cystic Fibrosis Foundation to fund this trial.